12 results about "Germinal center" patented technology

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The present invention relates to glycosylate HIV timer nanoparticles fused to self-assembling ferritin proteins which may be utilized as immunogens to enhance trafficking to lymph nodes and germinal centers and to heighten immune responses.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

The invention discloses application of an SETD8 inhibitor in preparation of a medicine for treating diffuse large B-cell lymphoma, and belongs to the technical field of biological medicine. The SETD8 inhibitor is preferably UNC0379, and the diffuse large B-cell lymphoma comprises a hair growth center B-cell-like lymphoma and a non-hair growth center B-cell-like lymphoma. The medicine prepared from the SETD8 inhibitor can effectively inhibit proliferation of diffuse large B-cell lymphoma cells, induce apoptosis of the diffuse large B-cell lymphoma cells and inhibit growth of in-vivo diffuse large B-cell lymphoma tumor cells. The invention also provides a pharmaceutical composition for treating diffuse large B-cell lymphoma, which comprises the SETD8 inhibitor as an active component and is supplemented with a pharmaceutically acceptable carrier or auxiliary material. The application range of the SETD8 inhibitor is expanded, a new drug choice is provided for solving the problem that in an existing treatment scheme, drug resistance or relapse of a diffuse large B-cell lymphoma patient is prone to occurring, and the SETD8 inhibitor has important clinical application value.

Provided herein are methods of treating diseases (e.g., proliferative disease (e.g., cancer (e.g., breast cancer, colon cancer, testicular cancer, CNS cancer, stomach cancer, lymphoma (e.g., B-cell lymphoma (e.g., lymphoplasmacytic lymphoma (e.g., IgM secreting lymphoplasmacytic lymphoma (i.e., Waldenstrom's Macroglobulinemia), non-IgM secreting lymphoplasmacytic lymphoma)), diffuse large B-cell lymphoma (e.g., activated B-cell-like (ABC)-DLBCL, germinal center B-cell-like (GBC)-DLBCL), follicular lymphoma, marginal zone B-cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma), and leukemia (e.g., chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia, myelogenous leukemia (e.g., chronic myelogenous leukemia, acute myelogenous leukemia))))) comprising administering to the subject in need thereof a therapeutically effective amount of Compound (I). Further provided are methods for treating disease resistant to treatment with BTK inhibitors (e.g., ibmtinib). Formula (I)

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.

The application discloses a use of ursolic acid as a SARS-CoV-2 subunit vaccine adjuvant, aims to solve the technical problems of relatively weak immunogenicity of existing subunit vaccines, possible local or systemic adverse reactions of some adjuvants and unclear action mechanism, and provides a new medical use of ursolic acid. The ursolic acid can effectively improve the antigen-specific antibody level of the subunit vaccine immunized mice, promote the formation of germinal centers and enhance follicular helper T cell response. The action mechanism is that after the ursolic acid is combined with PTPRF, the stability of the PTPRF is affected and the degradation of the PTPRF is promoted, thereby enhancing the downstream STAT3 phosphorylation, promoting the expression of antigen presentation related genes and improving the antigen presentation ability of the dendritic cells, and finally enhancing the antibody response of the body. The application provides a new subunit vaccine adjuvant candidate molecule for preventing severe SARS-CoV-2 related infections in clinic, and provides a new molecular target and mechanism basis for the development of subunit vaccine adjuvants.

This application discloses an application of a functional organ typing system based on human immune organoids in rheumatoid arthritis (RA), relating to the field of biomedical technology. This application develops a functional organ typing system based on human immune organoids. Using this model, the in vivo immune imbalance characteristics of RA are successfully reproduced. The in vitro state of T and B lymphocytes in RA patients is simulated, including germinal center formation, autoantibody secretion, inflammatory cytokine production, and immune cell interactions. Establishing such organoid models helps to more comprehensively elucidate the pathogenesis of rheumatoid arthritis and identify novel therapeutic targets associated with these immune cell populations.

The invention relates to the technical field of biological medicines, and particularly discloses an organoid simulating a lymphatic epithelial tissue structure and application thereof. The organoid comprises an immune micro-region capable of supporting B cell activation, somatic mutation and / or the formation of a hair growth center-like structure, and the organoid is derived from a cell population of lymph-related tissue. According to the method, a Transwell three-dimensional culture system supported by a low-concentration matrix is adopted, and optimized culture conditions are combined, so that B cells are promoted to form a hair growth center-like structure in an organoid. The method can be applied to mucosal immune mechanism research, vaccine or immunologic adjuvant evaluation, immunomodulatory drug screening, antibody discovery and screening, hair growth center related immune response research and the like.

The invention provides a fusion gene and an HPV nucleic acid vaccine. A fusion gene is obtained through research and optimization, and the fusion gene is obtained by sequentially connecting an L1 gene of an HPV 16 type, an E5 gene, an E6 gene and an E7 gene of the HPV 16 type and an E5 gene, an E6 gene and an E7 gene of an HPV 52 type. The inventor finds that an HPV vaccine prepared by taking the fusion gene as an antigen component can effectively promote cellular immune response and formation of long-term protective memory, promote hair growth center response and formation of humoral immune memory, remarkably improve the proportion of NKT cells, successfully activate systemic anti-tumor cell immune response of mice, and improve the anti-tumor effect of the mice. The anti-tumor immune effect is greatly improved. The traditional Chinese medicine composition has the dual effects of prevention and treatment, has the prevention capability, can effectively inhibit tumor growth and has the tumor treatment capability. The HPV vaccine also has the advantages of high safety, good stability and the like, and has a wide application prospect.

Described herein is an engineered viral subunit vaccine encoding ASFV capsid proteins (e.g., P72 and Penton) for use in pigs. The vaccine with either P72 or Penton tested in mice elicited significantly higher levels of antigen-specific IgM and IgG, increased frequency of antibody-secreting cells in the bone marrow, and higher quality germinal centers in the spleens of immunized mice. Enhanced T cell responses were also observed, with higher levels of IFN-γ and TNF-α in splenocytes. Immunogenicity assessments in pigs further supported these findings, with both MB-P72 and MB-PN180Q inducing robust B cell and T cell responses. These findings show that expression of capsid proteins P72 and Penton in membrane-bound forms via mRNA preserves their native multimeric structure and enhances their immunogenicity and provides a basis for an effective ASFV vaccine.

The invention discloses an application of a benzoylguanidine derivative in preparation of a medicine for treating and / or preventing chronic inflammatory diseases. According to the invention, the benzoylguanidine derivative is prepared into a hydrogel dosage form, and the hydrogel dosage form acts on a psoriasis affected part in a smearing manner, so that psoriasis-like skin lesion symptoms such as skin scales, erythema and epidermis thickening can be relieved, skin inflammatory cell infiltration and epidermis thickness can be relieved, spleen inflammatory cell infiltration can be relieved, and abnormal activity of a hair growth center can be improved; the traditional Chinese medicine composition reduces inflammatory reactions such as spleen index, reduces the level of inflammatory factors in plasma and spleen, and shows a good psoriasis treatment effect. Therefore, the benzoylguanidine derivative and the hydrogel preparation thereof have the remarkable advantages of safety, few toxic and side effects and no pollution of drug residues, and have a remarkable treatment effect and potential for realizing medical transformation.